QDSA (Quantitative Digital Subtraction Angiography)
QDSA (Quantitative Digital Subtraction Angiography): QDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.
Study summary
Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.
Eligibility
Sex
ALL
Min age
1 Year
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Cerebrovascular diseases diagnosed and assessed by DSA for related risks and treatment options.
2. The DSA acquisition protocol complies with the standard procedure.
3. DSA images must include complete anteroposterior and lateral views.
4. Raw data must be available in DICOM format.
5. Image quality and pixel resolution must support data analysis.
6. Patients must undergo regular follow-ups.
Exclusion Criteria:
1. Cerebrovascular diseases not diagnosed or risk-assessed using DSA.
2. Patients with DSA image quality insufficient for image analysis and processing.
3. Severe organ diseases with an expected survival period of less than 2 years.
4. Inability to cooperate with treatment and follow-up.
5. Participation in other clinical trials within the past 6 months.
6. Other conditions deemed by the investigator as unsuitable for participation in this trial.
Primary outcome measure(s)
Symptomatic stroke or death — After treatment (max 10 years) Stroke is defined as a clinically symptomatic event (any new focal neurological deficit, seizure, or new-onset headache) that is associated with imaging findings of hemorrhage or infarction. Hemorrhage is defined as fresh intracranial blood on head computed tomography (CT) or magnetic resonance imaging (MRI), or in the cerebrospinal fluid. Infarction is defined as a new ischemic lesion on cranial CT or MRI (diffusion-weighted, T2-weighted, or fluid-attenuated inversion recovery MRI).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.